Other Events ·
Spyre Therapeutics announced positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial for…
SYRESpyre Therapeutics, Inc.
Spyre Therapeutics announced positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial for SPY002, targeting moderately-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.7-point reduction in the Robarts Histopathology Index (p<0.0001). Clinical remission was achieved in 33% of participants, and 42% showed endoscopic improvement. The safety profile was consistent with the TL1A class, with 41.7% of subjects experiencing any adverse event and two serious adverse events reported, both deemed not drug-related. Spyre Therapeutics is a biotechnology company developing therapies for inflammatory diseases.